Your browser doesn't support javascript.
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Mentzer, Alexander J; O'Connor, Daniel; Bibi, Sagida; Chelysheva, Irina; Clutterbuck, Elizabeth A; Demissie, Tesfaye; Dinesh, Tanya; Edwards, Nick J; Felle, Sally; Feng, Shuo; Flaxman, Amy L; Karp-Tatham, Eleanor; Li, Grace; Liu, Xinxue; Marchevsky, Natalie; Godfrey, Leila; Makinson, Rebecca; Bull, Maireid B; Fowler, Jamie; Alamad, Bana; Malinauskas, Tomas; Chong, Amanda Y; Sanders, Katherine; Shaw, Robert H; Voysey, Merryn; Snape, Matthew D; Pollard, Andrew J; Lambe, Teresa; Knight, Julian C.
  • Mentzer AJ; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. alexander.mentzer@ndm.ox.ac.uk.
  • O'Connor D; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Bibi S; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Chelysheva I; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Clutterbuck EA; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Demissie T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Dinesh T; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Edwards NJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Felle S; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Feng S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Flaxman AL; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Karp-Tatham E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Li G; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Liu X; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Marchevsky N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Godfrey L; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Makinson R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Bull MB; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Fowler J; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Alamad B; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Malinauskas T; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Chong AY; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Sanders K; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Shaw RH; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Voysey M; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Snape MD; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Lambe T; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Knight JC; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nat Med ; 2022 Oct 13.
Article in English | MEDLINE | ID: covidwho-2233232
ABSTRACT
SARS-CoV-2 vaccine immunogenicity varies between individuals, and immune responses correlate with vaccine efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 vaccine efficacy trials in the United Kingdom, we find that inter-individual variation in normalised antibody responses against SARS-CoV-2 spike (S) and its receptor binding domain (RBD) at 28 days following first vaccination shows genome-wide significant association with major histocompatibility complex (MHC) class II alleles. The most statistically significant association with higher levels of anti-RBD antibody was HLA-DQB1*06 (P = 3.2 × 10-9), which we replicate in 1,677 additional vaccinees. Individuals carrying HLA-DQB1*06 alleles were less likely to experience PCR-confirmed breakthrough infection during the ancestral SARS-CoV-2 virus and subsequent Alpha-variant waves compared with non-carriers (HR 0.63, 0.42-0.93, P = 0.02). We identify a distinct S-derived peptide that is predicted to bind differentially to HLA-DQB1*06 compared with other similar alleles, and find evidence of increased spike-specific memory B-cell responses in HLA-DQB1*06 carriers at 84 days following first vaccination. Our results demonstrate association of HLA type with COVID-19 vaccine antibody response and risk of breakthrough infection, with implications for future vaccine design and implementation.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-02078-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-02078-6